Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1097/hs9.0000000000000900 | Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance |
| https://doi.org/10.1128/jcm.00873-23 | A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC |
| https://doi.org/10.1097/hs9.0000000000000524 | Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future |
| https://doi.org/10.1097/hs9.0000000000000842 | A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care |
| https://doi.org/10.1016/s2352-3026(23)00182-5 | Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective |
| https://doi.org/10.5334/johd.124 | Datasheets for Digital Cultural Heritage Datasets |
| https://doi.org/10.1097/hs9.0000000000000488 | Fair Pricing of Innovative Medicines: An EHA Position Paper |
| https://doi.org/10.3324/haematol.2015.136739 | The European Hematology Association Roadmap for European Hematology Research: a consensus document |
| https://doi.org/10.1097/hs9.0000000000000487 | Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation |
| https://doi.org/10.1055/s-0040-1718583 | Data Collection during the COVID-19 Pandemic: Learning from Experience, Resulting in a Bayesian Repertory |
| https://doi.org/10.1136/esmoopen-2019-000611 | EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies |
| https://doi.org/10.1097/hs9.0000000000000520 | EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia |
| https://doi.org/10.1097/hs9.0000000000000724 | Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force |
| https://doi.org/10.1038/s41591-025-04055-1 | Reduce bureaucracy in clinical trials now |
| https://doi.org/10.1002/hem3.70226 | Burnout symptoms among hematology professionals: An EHA survey |
| https://doi.org/10.1182/bloodadvances.2025017081 | Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe |
| https://doi.org/10.3324/haematol.2012.078964 | H-Net, the European Network for Harmonization of Training in Hematology, and its policy |
| https://doi.org/10.1038/s41409-023-02072-7 | Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy—a guidance by the GoCART Coalition Pharmacist Working Group |
| https://doi.org/10.3324/haematol.2012.067942 | Towards a joint definition of European hematology |
| https://doi.org/10.1111/trf.17764 | The 2023 AABB international guidelines for red blood cell transfusions: What is new? |
| https://doi.org/10.3389/fimmu.2025.1567582 | European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring |
| https://doi.org/10.1002/hem3.70306 | The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies |
| https://doi.org/10.1515/cclm-2022-1051 | The gaps between the new EU legislation on in vitro diagnostics and the on-the-ground reality |
| https://doi.org/10.1586/ehm.10.55 | 15th Congress of European Hematology Association |
| https://doi.org/10.3324/haematol.2013.103424 | Remembering John M. Goldman |
| https://doi.org/10.3324/haematol.2013.090415 | Age and aging in blood disorders: EHA theme of the year 2013-2014 |
| https://doi.org/10.1097/hs9.0000000000000865 | Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities |
| https://doi.org/10.3390/jmahp12030011 | The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy |
| https://doi.org/10.3390/jmahp13010006 | Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy |
| https://doi.org/10.1002/hem3.70243 | Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee |
| https://doi.org/10.1016/j.jcpo.2025.100700 | Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum |
| https://doi.org/10.1016/j.eclinm.2026.103929 | A Europe-wide provider perspective of healthcare services for adolescent and young adult patients with haematological conditions: a survey from the Adolescent and Young Adult Taskforce of the European Hematology Association |
| https://doi.org/10.1016/s2352-3026(16)30074-6 | Costs of haematological disease high and rising |
| https://doi.org/10.3324/haematol.2012.080796 | Quality of Life in hematology: European Hematology Association theme of the year ... and years to come |
| https://doi.org/10.1097/hs9.0000000000000477 | Access to Affordable Orphan Medicines in Europe: An EHA Position Paper |
| https://doi.org/10.3324/haematol.2014.104299 | Survey of professional competence in hematology in Europe |
| https://doi.org/10.1182/blood-2022-157549 | Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects |
| https://doi.org/10.1002/hem3.70204 | Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe |
| https://doi.org/10.1002/cpt.70213 | Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data |
| https://doi.org/10.1177/00178969211035169 | Co-creating an empowering health education intervention for urological cancer patients |
| https://doi.org/10.1097/hs9.0000000000000291 | The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe |
| https://doi.org/10.1016/j.jval.2022.04.1729 | Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools |
| https://doi.org/10.3324/haematol.2011.057257 | Raising hematology's European voice: the importance of calling yourself a hematologist |
| https://doi.org/10.1097/hs9.0000000000000049 | The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility |
| https://doi.org/10.18620/ctt-1866-8836-2019-8-2-82-90 | Highlights of the 24th European Hematology Association Congress, Amsterdam 2019 |
| https://doi.org/10.1097/hs9.0000000000000354 | Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next? |
| https://doi.org/10.12816/0003166 | Chronic Myeloid Leukaemia : A Paradigm for Malignancy or Just a Strange Disease ? = الإبيضاض النخاعي المزمن : نموذج لورم خبيث أو مجرد مرض غريب ؟ |
| https://doi.org/10.1097/hs9.0000000000000298 | Delivering on the Promise: Innovative Therapies and the Quest for (Real) Patient Benefit |
| https://doi.org/10.1097/hs9.0000000000000702 | Addressing Inequality of Access to Biologics: What Is Your Role? A Patient (Advocate)’s Perspective on Biosimilars |
| https://doi.org/10.1097/hs9.0000000000000765 | How a Medical Association Can Make a Difference in a Crisis Situation |
| https://doi.org/10.1002/hem3.70108 | European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies |
| https://doi.org/10.33590/emjhematol/gfpq3502 | EHA 2025 Interview: Martin Dreyling |
| https://doi.org/10.1002/hem3.70239 | Patient‐centered and proportionate safety reporting in clinical trials facilitates evidence‐based medicine for the benefit of patients and society: An EHA priority |
| https://doi.org/10.1159/000479547 | Making Change Happen in Health |
| https://doi.org/10.1159/000481565 | The Long and the Short of Missing Medicines |
| https://doi.org/10.1097/hs9.0000000000000365 | EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology |
| https://doi.org/10.1016/j.htct.2021.10.1067 | EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG |
| https://doi.org/10.2217/fmeb2013.13.135 | Cytogenetic features in myelodysplastic syndromes |
| https://doi.org/10.3324/haematol.2016.142018 | Blood disorders stepping into the limelight |
| https://doi.org/10.1128/jcm.01625-23 | Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion” |
| https://doi.org/10.1097/hs9.0000000000000274 | EBV & lymphoma |
| https://doi.org/10.21203/rs.3.rs-3961968/v1 | Delphi hackathon – a new approach to develop Core Outcome Sets for blood cancers |
| https://doi.org/10.12968/hmed.2015.76.8.442 | European Hematology AssoCiation Vienna, austria, 11–14 June |
| https://doi.org/10.1097/hs9.0000000000000017 | Hematology and Big Data: Enabling Better and Faster Treatment |
| https://doi.org/10.1097/hs9.0000000000000046 | How Talent Acceleration Generated Talent Advocacy |
| https://doi.org/10.29328/journal.ijbmr.1001011 | Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels |
| https://doi.org/10.1097/hs9.0000000000000500 | Change is Coming: Plan S From the Early Career Scientist Perspective |
| https://doi.org/10.1182/blood-2021-145002 | Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance |
| https://doi.org/10.1007/978-3-030-94353-0_43 | GoCART |
| https://doi.org/10.1097/hs9.0000000000000743 | The Updated European Hematology Association Research Roadmap |
| https://doi.org/10.1097/01.hs9.0000848632.89484.3a | P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION |
| https://doi.org/10.1097/hs9.0000000000000777 | The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group |
| https://doi.org/10.1097/hs9.0000000000000815 | The Progress Test of the European Hematology Association: A New Tool for Continuous Learning |
| https://doi.org/10.35376/10324/59908 | Importancia del perfil inflamatorio-molecular en la infección por SARS-COV-2 y su relación con el grupo sanguíneo ABO. |
| https://doi.org/10.1016/j.jval.2023.09.241 | CO169 Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies in the Framework of the EU Project, Harmony: the Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology |
| https://doi.org/10.1016/j.jcyt.2024.03.223 | T2EVOLVE: STANDARDIZATION OF PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ENGINEERED T CELL THERAPY IN EUROPE; A CROSS FUNCTIONAL MULTI STAKEHOLDER INITIATIVE |
| https://doi.org/10.33590/emjhematol/pgqp6795 | EHA Congress Interview: Elizabeth Macintyre |
| https://doi.org/10.18295/2075-0528.1401 | Chronic Myeloid Leukaemia : A paradigm for malignancy or just a strange disease? |
| https://doi.org/10.1016/j.esmoop.2025.104374 | 61MO Perceptions of healthcare professionals and regulators on the use of real-world data as external comparators in late-stage oncology single-arm trials |
| https://doi.org/10.1182/hem.v22.4.2025415 | Unifying Threads: ASH and EHA Collaborate to Support Hematologists |
| https://doi.org/10.33590/emjhematol/ebsj8988 | EHA 2025 Interview: Konstanze Döhner |
| https://doi.org/10.1016/j.jcyt.2025.09.007 | Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe |
| https://doi.org/10.1002/hem3.70380 | An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non‐malignant hematological diseases |
| https://doi.org/10.5334/johd.571 | Dataset Context(ualisation) in Documentation: Best Practices, Recommendations and Open Questions |
| https://doi.org/10.1002/zoo.70116 | Isolated Demes as a Genetic Management Strategy for Ex Situ Conservation Programs |